A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Tirzepatide (Primary)
- Indications Obesity; Sleep apnoea syndrome
- Focus Therapeutic Use
- Acronyms SURMOUNT-OSA
- Sponsors Eli Lilly and Company
- 21 Jun 2024 According to an Eli Lilly and Company Media Release, the company has submitted Lilly submitted tirzepatide for the treatment of moderate-to-severe OSA and obesity to the U.S. Food and Drug Administration (FDA) with regulatory action anticipated as early as the end of this year.
- 21 Jun 2024 Results presented in the Eli Lilly and Company Media Release.
- 21 Jun 2024 According to American Diabetes Association media release, results were presented as a Late-Breaking Symposium at the 84th Scientific Sessions of the American Diabetes Association (ADA) in Orlando, FL, and were simultaneously published in the New England Journal of Medicine (NEJM).